The Technical Analyst
Cognition Therapeutics, [CGTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cognition Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.16% $1.840
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 71.76 mill |
| EPS: | -0.860 |
| P/E: | -2.14 |
| Earnings Date: | May 04, 2024 |
| SharesOutstanding: | 39.00 mill |
| Avg Daily Volume: | 0.206 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.14 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.36x |
| Company: PE -2.14 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.991 (-46.16%) $-0.849 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.704 - 1.976 ( +/- 7.39%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-14 | Ricciardi Lisa | Buy | 5 700 | Common Stock |
| 2024-02-15 | Doyle John Brendan | Buy | 20 000 | Common Stock |
| 2024-02-15 | Doyle John Brendan | Buy | 20 000 | Stock Option (Right to Buy) |
| 2024-02-15 | Caggiano Anthony | Buy | 60 000 | Common Stock |
| 2024-02-15 | Caggiano Anthony | Buy | 60 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 97.09 |
| Last 94 transactions |
| Buy: 12 730 714 | Sell: 1 480 989 |
Forecast:
16:00 - $1.820
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.820
Forecast 2: 16:00 - $1.820
Forecast 3: 16:00 - $1.820
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.840 (-3.16% ) |
| Volume | 0.0991 mill |
| Avg. Vol. | 0.206 mill |
| % of Avg. Vol | 48.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CGTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Latest Press Releases
2024-04-02 07:30:00 - Press Release
Cognition Therapeutics To Present At The Needham Virtual Healthcare Conference
Purchase, n.y., april 02, 2024 (globe newswire) -- cognition therapeutics, inc. (the “company” or “cognition”) (nasdaq: cgtx), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the company's president and ceo, lisa ricciardi, will present at the 23rd annual needham virtual healthcare conference taking place april 8-11, 2024. during her presentation, ms. ricciardi will review recent corporate accomplishments and anticipated clinical milestones.
2024-04-01 07:30:00 - Press Release
Cognition Therapeutics To Host Virtual Kol Event On The Evolving Landscape In Alzheimer's Disease On April 12, 2024
New york, april 01, 2024 (globe newswire) -- cognition therapeutics, inc. (the “company” or “cognition”) (nasdaq: cgtx), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced it will host a virtual kol event on friday, april 12, 2024 from 8:00 am to 9:30 am et. the live and archived event may be accessed from the investor relations section of the cognition website. to register, please click here .
2024-03-26 07:00:00 - Press Release
Cognition Therapeutics Reports Year End 2023 Financial Results And Provides Business Update
- topline results from shine study in mild-to-moderate alzheimer's expected mid-2024 - - on track to report topline results from shimmer study in mild-to-moderate dlb in 2h 2024 - - 1q 2024 capital raise extends cash runway through may 2025 - - webcast conference call scheduled today at 8:00 a.m. et -
2024-03-15 07:30:00 - Press Release
Cognition Therapeutics To Report Fourth Quarter And Full Year 2023 Results
Purchase, n.y., march 15, 2024 (globe newswire) -- cognition therapeutics, inc. (nasdaq: cgtx), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the company will release financial results for the fourth quarter and full year ended december 31, 2023 on tuesday, march 26, 2024 before the market open.
2024-03-14 16:05:00 - Press Release
Cognition Therapeutics Announces Closing Of $11.5 Million Public Offering Of Common Stock
Purchase, n.y., march 14, 2024 (globe newswire) -- cognition therapeutics, inc. (“cognition,” the “company” or “we”) (nasdaq: cgtx), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock. each share of common stock was sold at a price to the public of $1.75 per share. the gross proceeds to the company from the offering were approximately $11.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company. the company intends to use the net proceeds from this offering to fund research, clinical development, process development and manufacturing of cognition's product candidates, working capital, capital expenditures and other general corporate purposes.
Latest News
2024-04-02 07:30:00 - GlobeNewsWire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones.
2024-03-15 07:30:00 - GlobeNewsWire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open.
2024-02-26 07:30:00 - GlobeNewsWire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition's pipeline progress, including upcoming clinical milestones and recent corporate achievements.
2023-08-12 23:21:02 - Seeking Alpha
Cognition Therapeutics, Inc. (CGTX) Q2 2023 Earnings Call Transcript
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer John Doyle - Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head, R&D Conference Call Participants Charles Duncan - Cantor Jay Olson - Oppenheimer Aydin Huseynov - Ladenburg Operator Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Jenny and I will be your conference operator today.
2023-08-02 07:30:00 - GlobeNewsWire
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review financial results and provide a business update.
2023-06-27 19:17:00 - GlobeNewsWire
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative disorders by regulating cellular damage response pathways, announced that it will host a conference call and webcast on June 28, 2023, at 8:00am ET to discuss topline results from its Phase 2 SEQUEL Study (NCT04735536) for mild-to-moderate Alzheimer's disease. During the event, members of Cognition's leadership team and a principal investigator from the trial will review the results.
2023-04-19 07:30:00 - GlobeNewsWire
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023
NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which have been shown to regulate key cellular processes involved in age-related degenerative diseases.
2023-03-23 09:26:10 - Seeking Alpha
Cognition Therapeutics, Inc. (CGTX) Q4 2022 Earnings Call Transcript
Cognition Therapeutics, Inc. (NASDAQ:CGTX ) Q4 2022 Earnings Conference Call March 23, 2023 8:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Andrew Einhorn - Interim Chief Financial Officer Tony Caggiano - Chief Medical Officer and Head of R&D Conference Call Participants Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Operator Good morning, ladies and gentlemen, and welcome to Cognition Therapeutics Incorporated Fourth Quarter and Fiscal Year 2022 Earnings Conference Call.
2023-03-21 08:00:00 - GlobeNewsWire
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023
- CEO Participating on Panel Hosted by Alzheimer's Drug Discovery Foundation - - CEO Participating on Panel Hosted by Alzheimer's Drug Discovery Foundation -
2023-03-16 12:18:00 - GlobeNewsWire
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET